Johnson & Johnson's TREMFYA (guselkumab) demonstrated significantly higher combined fistula remission rates in adults with perianal fistulizing Crohn's disease at Week 24 compared to placebo in the Phase 3 FUZION study. This marks the first randomized controlled trial in 20 years to show efficacy for this challenging Crohn's disease complication, offering hope for improved management of a debilitating condition. The study's positive results support TREMFYA as a new treatment option, with ongoing research including a head-to-head trial against another IL-23 inhibitor underway.
California retirees with dividend portfolios face significant state taxes that reduce their net income by about 23%, compared to states like Florida where the tax burden is much lower. Dividend yields vary by investment strategy: conservative portfol...
The Vanguard Dividend Appreciation Index Fund ETF (VIG) has posted a modest 5% gain year-to-date, underperforming the broader market due to rising long-term Treasury yields, which compete with dividend yields. While dividend growth continues, investo...
The FT Vest S&P 500 Dividend Aristocrats Target Income ETF (KNG) uses covered calls on Dividend Aristocrats stocks to deliver an 8.6% yield, appealing to retirees seeking income. However, this strategy caps upside gains, causing KNG to underperform t...
Johnson & Johnson and AbbVie both exceeded Q1 2026 revenue expectations, prompting them to raise their full-year guidance. JNJ's growth was driven by diversified pharma and MedTech segments, notably TREMFYA and cardiovascular products, while AbbVie r...
Vanguard Dividend Appreciation ETF (VIG) is often overlooked due to its low current yield of about 1.6%, but it focuses on companies with a strong history of dividend growth rather than high initial payouts. The fund tracks the S&P U.S. Dividend Grow...
